Alessandra Luchini

8382987, Feb 26, 2013

Aug 19, 2008

12/194371

Alessandra Luchini - Fairfax VA, US
Lance Liotta - Bethesda MD, US
Emanuel Petricoin - Gainesville VA, US
Barney Bishop - Annandale VA, US
Francesco Meani - Fairfax VA, US
Claudia Fredolini - Bristow VA, US
Thomas M Dunlap - Round Hill VA, US
Alexis Patanarut - Burke VA, US

B01D 39/16

210635

Capture particles for harvesting analytes from solution and methods for using them are described. The capture particles are made up of a polymeric matrix having pore size that allows for the analytes to enter the capture particles. The pore size of the capture particles are changeable upon application of a stimulus to the particles, allowing the pore size of the particles to be changed so that analytes of interest remain sequestered inside the particles. The polymeric matrix of the capture particles are made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. The capture particles may be used to isolate and identify analytes present in a mixture. They may also be used to protect analytes which are typically subject to degradation upon harvesting and to concentrate low an analyte in low abundance in a fluid.

8497137, Jul 30, 2013

Aug 19, 2008

12/194360

Alessandra Luchini - Fairfax VA, US
Lance Liotta - Bethesda MD, US
Emanuel Petricoin - Gainesville VA, US
Barney Bishop - Annandale VA, US
Caterina Longo - Fairfax VA, US
Virginia Espina - Rockville MD, US
Alexis Patanarut - Burke VA, US

G01N 33/545

436531, 42840224, 428407, 435 61, 436534, 436535

Capture particles for harvesting analytes from solution and methods for using them are described. The capture particles are made up of a polymeric matrix having pore size that allows for the analytes to enter the capture particles. The pore size of the capture particles are changeable upon application of a stimulus to the particles, allowing the pore size of the particles to be changed so that analytes of interest remain sequestered inside the particles. The polymeric matrix of the capture particles are made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. The capture particles may be used to isolate and identify analytes present in a mixture. They may also be used to protect analytes which are typically subject to degradation upon harvesting and to concentrate low an analyte in low abundance in a fluid.

20090148961, Jun 11, 2009

Feb 19, 2008

12/033701

Alessandra Luchini - Fairfax VA, US
Lance Liotta - Bethesda MD, US
Emanuel Petricoin - Gainesville VA, US
David Geho - Doylestown PA, US

G01N 33/543
B01J 19/00
G01N 27/00
G01N 21/00
G01N 21/64
C12M 1/00
C08J 9/16

436518, 436178, 422 61, 422 8205, 422 8201, 422 8208, 4352872, 521 56

Capture particles for harvesting analytes from solution and methods for using them are described. The capture particles are made up of a polymeric matrix having pore size that allows for the analytes to enter the capture particles. The pore size of the capture particles may be changeable upon application of a stimulus to the particles, allowing the pore size of the particles to be changed so that analytes of interest remain sequestered inside the particles. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. The capture particles may be used to isolate and identify analytes present in a mixture. They may also be used to protect analytes which are typically subject to degradation upon harvesting and to concentrate low an analyte in low abundance in a fluid.

20110236999, Sep 29, 2011

Aug 26, 2009

13/061507

Lance A. Liotta - Bethesda MD, US
Alessandra Luchini - Fairfax VA, US
Emaneul F. Petricoin - Gainesville VA, US
Virginia Espina - Rockville MD, US

G01N 33/543
B82Y 15/00

436518, 977773, 977902

An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.

20120107959, May 3, 2012

Jun 21, 2010

13/379345

Lance Liotta - Bethesda MD, US
Virginia Espina - Rockville MD, US
Alessandra Luchini - Burke VA, US
Davide Tamburro - Bristow VA, US

G01N 21/75

436501

This invention describes the identification of novel organic dye chemistries that can be used as affinity baits to capture proteins and other biomolecules useful in the fields of medical diagnostics, environmental science, toxicology, and infectious disease. Incorporation of unique affinity dye compounds within hydrogel capture particles improves analyte yield and preanalytical precision, and stabilizes the analyte against degradation, while increasing measurement sensitivity. The particles in this invention can be used for routine clinical testing as well as for discovery of low abundance disease biomarkers. Example hydrogel particles containing new high affinity bait chemistries were used to identify a new set of human serum biomarkers.

20130085076, Apr 4, 2013

Dec 1, 2010

13/513568

Temple Douglas - Leesburg VA, US
Alessandra Luchini - Burke VA, US
Claudia Fredolini - Collegno, IT
Davide Tamburro - Rome, IT
Lance Liotta - Bethesda MD, US

G01N 33/569

506 9, 435 732, 436501, 435 792

The invention relates to both a sensitive method for the capture and detection of low-abundance (Bb) bacterial antigens allowing for the diagnosis of Lyme Disease using standard immunoassays. Furthermore, this invention allows the antigen to be identified in a sample of urine, serum, or other biological fluids isolated from humans and animals. The invention provides a method to capture, concentrate, separate and specifically quantify the abundance of Bb antigens using immunoassays. The detection of Bb Outer Surface Protein A is presented as an example of the disclosed invention. High sensitivity levels, low cost and easily collected biofluids allow this technology to reach patients in clinics as well as POC applications for the early detection of Lyme disease prior to seroconversion. A kit containing necessary reagents and the method for diagnosis, monitoring or assessing lyme disease using an immunoassay such as an ELISA, western blot or RPPMA is disclosed.

20190352351, Nov 21, 2019

Nov 18, 2016

15/776932

- Fairfax VA, US
Alessandra LUCHINI - Burke VA, US
Virginia ESPINA - Rockville MD, US
Mikell PAIGE - Fairfax VA, US

C07K 14/47
C07D 307/91

In one aspect, the invention relates to compositions comprising peptides and/or peptidomimetic compounds, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, arthritis, obstructive lung disease, psoriasis, asthma, a defect in hematopoiesis, a neoplasia, a fungal infection, a parasitic infection, or an autoimmune disease, such as, but not limited to, rheumatoid arthritis, atopic allergy, anaphylaxis, psoriasis, asthma, lupus erythematosis, a myeloid cell disorder, or a eosinophil cell disorder. In an aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the ST2 and IL33 receptor/cytokine complexes. In a further aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the IL-1R1 and IL-1β receptor/cytokine complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

20190250079, Aug 15, 2019

Apr 26, 2019

16/396191

- Fairfax VA, US
VIRGINIA ESPINA - Rockville MD, US
NITIN AGRAWAL - Fairfax VA, US
ALESSANDRA LUCHINI - Burke VA, US

G01N 1/28

Compositions and methods for the simulataneous capture and release using micropattern surfaces for tissue and cell microdissection. In one example, a patterned thermoplastic film has a first surface and a plurality of projections attached to and extending outwardly from the first surface. The projections form a pattern on the thermoplastic film.